Tag
The PROSA trial reveals that a contrast-free biparametric MRI-first screening approach doubles the detection of clinically significant prostate cancer compared to PSA-triggered pathways, while maintaining favorable cost-effectiveness and be
This review synthesizes findings from the MAESTRO-NASH trial, highlighting that Resmetirom’s efficacy is maintained alongside GLP-1 RAs and SGLT2 inhibitors, while being significantly enhanced by concurrent weight loss.
Explore the Phase 3 TROPION-Breast01 study results, detailing how the antibody-drug conjugate datopotamab deruxtecan offers a superior alternative to standard chemotherapy in advanced HR+/HER2- breast cancer through improved progression-fre
The OPTIC-2 phase 3b trial confirms that omadacycline is noninferior to moxifloxacin for treating community-acquired bacterial pneumonia (CABP). This once-daily aminomethylcycline offers a robust IV-to-oral monotherapy option with a favorab
Blarcamesine shows potential in slowing early Alzheimer’s progression, but questions about trial data robustness and transparency have been raised.
The Walk ‘n Watch trial shows that a structured, progressive walking protocol significantly improves endurance in subacute stroke patients, providing a 43.6-meter advantage over usual care without increasing serious adverse events.
A critical review of 29 breast cancer registrational trials reveals a significant gap in biomarker research dissemination, prompting a call for mandatory data and biospecimen sharing to accelerate personalized oncology and honor patient con
A post hoc analysis of the SCOPE I trial reveals that obstructive coronary artery disease (CAD) does not significantly impact 3-year survival or patient-reported health status following TAVR, questioning the routine necessity of periprocedu
A systematic review of 347 randomized trials reveals that non-industry-sponsored trials lag significantly behind industry counterparts in registration and results publication, with nearly one-third of all trials discontinued prematurely due
The AZA-PD phase 2 trial found that while azathioprine was well-tolerated in early Parkinson’s disease, it did not significantly improve gait-axial scores. However, exploratory data suggests potential motor benefits in female patients
The HOVON 158/NEXT STEP phase 2 trial demonstrates that a measurable residual disease (MRD)-guided intensification strategy using ibrutinib and obinutuzumab significantly deepens remissions in first-line CLL patients who do not achieve deep
The final 5-year analysis of the HOPE-B trial confirms that etranacogene dezaparvovec provides stable, long-term factor IX expression and clinical protection for patients with hemophilia B, effectively eliminating the need for routine proph
Longitudinal tau-PET accumulation follows distinct regional patterns across biological AD stages; aligning trial inclusion and outcome ROIs to baseline tau stage can substantially reduce sample sizes and improve power for disease-modifying
The NCI convened experts to provide clinical-trial design recommendations for biochemically recurrent prostate cancer in the era of PSMA PET, defining PSMA+BCR, high-risk criteria, imaging and data standards, endpoint suggestions, and a pus
Three multinational phase 3 trials found no clinically meaningful cognitive benefit of the GlyT1 inhibitor iclepertin versus placebo in schizophrenia, though the drug was well tolerated. Results highlight methodological and biological chall
An international Delphi consensus produced standardized morphological definitions and practical guidance to improve investigator lesion assessment in hidradenitis suppurativa clinical trials, enhancing reliability and trial data quality.
A multidisciplinary Delphi panel produced consensus morphological definitions and practical guidance to standardize investigator lesion assessments in hidradenitis suppurativa (HS) clinical trials — improving reliability of endpoints such a
A concise guide to the newly published Core Outcome Set for Post COVID-19 Condition (COS‑PCC): the nine prioritized outcomes, recommended measurement instruments, timing considerations, and implications for research and care.
An international Delphi consensus defined a Core Outcome Measurement Set (COMS) for dengue trials to harmonise outcome selection and measurement across settings, improving comparability and evidence synthesis.
A cross-sectional analysis (FDA approvals 2015–2018) found that most countries hosting pivotal trials lack timely market authorization for tested medicines, especially lower- and middle-income countries—raising ethical, regulatory, and poli
